Siddiqui Sameer A, Sengupta Shomik, Slezak Jeffrey M, Bergstralh Eric J, Zincke Horst, Blute Michael L
Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
J Urol. 2006 Sep;176(3):1118-21. doi: 10.1016/j.juro.2006.04.077.
Men with a family history of prostate cancer are at higher risk for prostate cancer. There are conflicting data regarding the impact of hereditary forms of prostate cancer on long-term outcomes after radical prostatectomy. We examined the impact of familial and hereditary prostate cancer treatment in the prostate specific antigen era.
Patients who underwent radical prostatectomy for prostate cancer from 1987 to 1997 were surveyed (3,560 responders) to determine the family history of prostate cancer. Patients were categorized as having familial prostate cancer if they had at least 1 first-degree relative with prostate cancer. Hereditary prostate cancer was defined as nuclear families with 3 cases of prostate cancer, families with prostate cancer in each of 3 generations and families with 2 men diagnosed before age 55 years. Sporadic prostate cancer was defined as patients with no family history. Clinical and pathological features, and long-term outcome measures, including biochemical recurrence-free, systemic progression-free and cancer specific survival, were compared among patients with familial, hereditary and sporadic prostate cancer.
A total of 865 and 133 patients were categorized as having familial prostate cancer and hereditary prostate cancer, respectively. Preoperatively prostate specific antigen was higher in patients with hereditary prostate cancer than in the other 2 groups (p = 0.04). Ten-year biochemical progression-free, systemic progression-free and cancer specific survival were equivalent.
Except for preoperative prostate specific antigen, clinicopathological features and long-term oncological outcomes are equivalent after radical prostatectomy in patients with familial, hereditary and sporadic prostate cancer.
有前列腺癌家族史的男性患前列腺癌的风险更高。关于遗传性前列腺癌对根治性前列腺切除术后长期预后的影响，存在相互矛盾的数据。我们研究了在前列腺特异性抗原时代，家族性和遗传性前列腺癌治疗的影响。
对1987年至1997年因前列腺癌接受根治性前列腺切除术的患者进行调查（3560名应答者），以确定前列腺癌家族史。如果患者至少有1名患前列腺癌的一级亲属，则被归类为患有家族性前列腺癌。遗传性前列腺癌定义为有3例前列腺癌患者的核心家庭、三代人中每代都有前列腺癌患者的家庭以及有2名男性在55岁之前被诊断为前列腺癌的家庭。散发性前列腺癌定义为无家族史的患者。比较家族性、遗传性和散发性前列腺癌患者的临床和病理特征以及长期预后指标，包括无生化复发、无全身进展和癌症特异性生存。
分别有865例和133例患者被归类为患有家族性前列腺癌和遗传性前列腺癌。遗传性前列腺癌患者术前前列腺特异性抗原高于其他两组（p = 0.04）。十年无生化进展、无全身进展和癌症特异性生存情况相当。
除术前前列腺特异性抗原外，家族性、遗传性和散发性前列腺癌患者根治性前列腺切除术后的临床病理特征和长期肿瘤学预后相当。
